pharma.markets

pharma.markets

  • HOME
  • Imprint

MS

Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care

26/10/2022 MaP 0

Merck will present 39 abstracts at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). • Company’s scientific leadership […]

Merck Highlights New Data for Evobrutinib…

26/10/2022 MaP 0

…First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment This data suggests the long-term positive […]

Spoiled oranges shine light on malignant cells

14/12/2021 MaP 0

Biomedical device passes the litmus test A University of Sydney PhD researcher is developing a cancer and serious disease-detecting biomedical probe that can be made […]

BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science

07/01/2021 MaP 0

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in […]

Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care

02/09/2020 MaP 0

• Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions • Antigen test accurately […]

Novartis provides update on FDA review of ofatumumab

03/06/2020 MaP 0

… a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis Novartis today announced that it has received notice from the US Food and […]

Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe

28/05/2020 MaP 0

• Reduces infusion time to 2 hours from the conventional 3.5 hours for patients with relapsing or primary progressive multiple sclerosis • EMA approval based […]

Novartis announces new late-breaking ofatumumab data

28/05/2020 MaP 0

…at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS) Rapid and profound depletion of B-cells contributed to […]

New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks

23/05/2020 MaP 0

• Investigational evobrutinib is the first and only Bruton’s Tyrosine Kinase inhibitor to demonstrate high and sustained efficacy through 108 weeks in clinical studies • […]

Translation

Search

Categories

  • Age.related Degeneration
  • Alzheimer
  • Animal health
  • Asthma
  • Bioscience
  • Cancer
  • Conferences
  • Cosmetics
  • COVID-19
  • EIB
  • EU
  • FCPA Investigations
  • FDA
  • Finance
  • Food
  • HHS
  • Humanitarian Aid
  • Imprint
  • Influenza
  • Innovation
  • Mental Health
  • MS
  • News
  • Research
  • Rheumatology
  • Space Science
  • Spain
  • Sports
  • Therapy
  • Trade Fair
  • UN
  • Vaccines
  • Valencia Comunidad
  • WHO

Reports

  • Bayer expands global clinical program for darolutamide in prostate cancer
  • Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
  • Pigs as Organ Donors – New Findings on the Prevention of Retrovirus Infections
  • Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer
  • New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)

Archive

  • March 2023 (15)
  • February 2023 (11)
  • January 2023 (6)
  • December 2022 (16)
  • November 2022 (11)
  • October 2022 (14)
  • September 2022 (1)
  • August 2022 (4)
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
  • Bayer expands global clinical program for darolutamide in prostate cancer

    23/03/2023 0
  • Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

    21/03/2023 0
  • Pigs as Organ Donors – New Findings on the Prevention of Retrovirus Infections

    20/03/2023 0
  • Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer

    20/03/2023 0
  • New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)

    20/03/2023 0
Archives
  • March 2023 (15)
  • February 2023 (11)
  • January 2023 (6)
  • December 2022 (16)
  • November 2022 (11)
  • October 2022 (14)
  • September 2022 (1)
  • August 2022 (4)
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
TAGS
affected africa aid bayer biontech cancer commission companies coronavirus covid-19 covid19 economy elpais.com emergency eu europe european fda food global guarantee health hygiene investment links medical merck novartis pandemic pfizer production recommendations region response roche safety scheme sector spain state statistics support test vaccine who

Copyright © 2023 | WordPress Theme by MH Themes

Cookie Consent with Real Cookie Banner